Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Youli Zhang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5019503335. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 11

  1. [Corrigendum] Furin promotes epithelial‑mesenchymal transition in pancreatic cancer cells via Hippo‑YAP pathway. Co-author DOI 10.3892/ijo.2025.5797↗
  2. The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. Co-author DOI 10.1002/1878-0261.12836↗
  3. Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.29308↗
  4. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells. Co-author DOI 10.1111/jcmm.14894↗
  5. The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Co-author PMID 30949406↗
  6. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway. Co-author DOI 10.1016/j.bbadis.2018.03.005↗
  7. Long non‑coding RNA PVT1 promotes epithelial‑mesenchymal transition via the TGF‑β/Smad pathway in pancreatic cancer cells. Co-author DOI 10.3892/or.2018.6462↗
  8. The mir-675-5p regulates the progression and development of pancreatic cancer via the UBQLN1-ZEB1-mir200 axis. First author DOI 10.18632/oncotarget.15330↗
  9. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway. Co-author DOI 10.3892/ijo.2017.3896↗
  10. MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.7507↗
  11. ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. Last author DOI 10.1016/j.canlet.2013.01.002↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aihua Gong · 10 shared papers, 2016–2025 · strength 0.99
  2. Min Xu · 10 shared papers, 2016–2025 · strength 0.99
  3. Wan‐Xin Peng · 6 shared papers, 2016–2025 · strength 0.61
  4. Lu Ge · 3 shared papers, 2016–2020 · strength 0.24
  5. Huizhi Wang · 2 shared papers, 2020–2021 · strength 0.23
  6. Huizhi Wang · 2 shared papers, 2019–2020 · strength 0.19
  7. Yawen Liu · 1 shared paper, 2021 · strength 0.12
  8. Jingyu Min · 1 shared paper, 2021 · strength 0.12
  9. Wei Chen · 1 shared paper, 2020 · strength 0.10
  10. Yawen Liu · 1 shared paper, 2019 · strength 0.09
  11. Meiting Zhang · 1 shared paper, 2018 · strength 0.08
  12. Xingxing Zhang · 1 shared paper, 2018 · strength 0.08
  13. Yu Xia · 1 shared paper, 2017 · strength 0.07
  14. Xingxing Zhang · 1 shared paper, 2017 · strength 0.07
  15. Jue Wang · 1 shared paper, 2017 · strength 0.07
  16. Yin‐Yuan Mo · 1 shared paper, 2016 · strength 0.05
  17. Xiangyu Kong · 1 shared paper, 2013 · strength 0.04
  18. Min Xu · 1 shared paper, 2013 · strength 0.04
  19. Lei Li · 1 shared paper, 2013 · strength 0.04
  20. Haojie Huang · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.